SurModics (SRDX) Tops Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance
November 10, 2021 7:30 AM ESTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022.
Summary of Fourth Quarter and Recent Highlights
Revenue of $24.0 million, an increase of 6% year-over-year GAAP EPS of $(0.02), non-GAAP EPS of $(0.10) Successful first patient use Sublime .018 RX PTA Dilatation CatheterWere extremely pleased to share that the Sublime and Pounce clinical product... More
